NAD+ NJ
Redox coenzyme
Redox coenzyme central to cellular energy metabolism and a substrate for sirtuins, PARP enzymes and CD38, studied in ageing biology.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- Redox coenzyme
- Category
- Mitochondrial & Longevity
- Type
- Single compound
- Abbreviation
- NJ
- Development and regulatory status
- Endogenous coenzyme; laboratory reagent; not an FDA-approved drug
What researchers study
Essential redox coenzyme in cellular energy metabolism and a substrate for sirtuins, PARP enzymes and CD38. Levels are reported to fall with age, which motivates research on NAD+-boosting precursors.
Research areas
- Cellular energy and redox metabolism
- Sirtuin and PARP enzyme-activity studies
- Ageing models in rodents
- NAD+ precursor pharmacology in human trials
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- review
A 2026 systematic review (33 human, 80 rodent studies) found NR and NMN precursors raised NAD-related metabolites in humans, but functional outcomes were heterogeneous and often null
- review
It found no eligible outcomes trials of parenteral NAD+ itself for anti-ageing or wellness
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- NAD+ + MOTS-c + 5-Amino-1MQCatalogue longevity blend containing NAD+
- 5-Amino-1MQNNMT inhibitor acting on nicotinamide and NAD+ salvage metabolism
- MOTS-c (Human)Mitochondrial peptide studied alongside NAD+ in cellular-energy research
- SS-31Mitochondrial-membrane peptide, complementary energy-metabolism pathway
